On May 12, 2025, President Trump issued an additional Executive Order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The Executive Order directs the Secretary of HHS to communicate most-favored-nation, or MFN, price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations.
All entries for: Apellis Pharmaceuticals, Inc.
February 24, 2026
Apellis Pharmaceuticals, Inc.
Neutral Outlook
Waltham, MA
501-1,000 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage.
Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule